AEON Biopharma

AEON Biopharma EBIT

The EBIT of AEON Biopharma (AEON) as of Nov 1, 2026 is -12.80 M USD. In the previous year, EBIT was 72.99 M USD — a change of -117.54% (lower).

EBIT

-12.80 MUSD

YoY

-117.54%

Last updated:

In 2025, AEON Biopharma's EBIT was -12.80 M USD, a -117.54% increase from the 72.99 M USD EBIT recorded in the previous year.

The AEON Biopharma EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2023
-348.09 M USD
Jan 1, 2024
72.99 M USD
Jan 1, 2025
-12.80 M USD
Jan 1, 2026 (e)
-35.80 M USD
Jan 1, 2027 (e)
-35.12 M USD
Jan 1, 2028 (e)
27.49 M USD
Jan 1, 2029 (e)
193.26 M USD
Jan 1, 2030 (e)
0.00 USD
The AEON Biopharma EBIT history
YEAREBITYoY
est0.00USD-100.00%
est193.26 MUSD+602.99%
est27.49 MUSD-178.29%
est-35.12 MUSD-1.90%
est-35.80 MUSD+179.60%
-12.80 MUSD-117.54%
72.99 MUSD-120.97%
-348.09 MUSD+618.76%
-48.43 MUSD-26.45%
-65.85 MUSD+301.80%
-16.39 MUSD-66.12%
-48.37 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AEON Biopharma Revenue

AEON Biopharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-348.09 M USD
-384.63 M USD
Jan 1, 2024
0.00 USD
72.99 M USD
42.01 M USD
Jan 1, 2025
0.00 USD
-12.80 M USD
-39.22 M USD
Jan 1, 2026 (e)
0.00 USD
-35.80 M USD
-234,802.13 USD
Jan 1, 2027 (e)
590,000.00 USD
-35.12 M USD
-139,333.13 USD
Jan 1, 2028 (e)
87.96 M USD
27.49 M USD
67,086.32 USD
Jan 1, 2029 (e)
309.57 M USD
193.26 M USD
412,838.90 USD
Jan 1, 2030 (e)
549.30 M USD
0.00 USD
789,554.36 USD

AEON Biopharma Margins

AEON Biopharma stock margins

The AEON Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AEON Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AEON Biopharma.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
- %
- %
Jan 1, 2027 (e)
100.00 %
-5,951.96 %
-23.62 %
Jan 1, 2028 (e)
100.00 %
31.26 %
0.08 %
Jan 1, 2029 (e)
100.00 %
62.43 %
0.13 %
Jan 1, 2030 (e)
100.00 %
0.00 %
0.14 %

AEON Biopharma Stock analysis

What does AEON Biopharma do? AEON Biopharma develops ABP-450, a proprietary 900 kDa botulinum toxin complex, targeting debilitating conditions including migraine, cervical dystonia, and gastroparesis. The company focuses on preventative treatment for chronic and episodic migraine, involuntary neck muscle contractions, and gastrointestinal disorders involving slowed stomach movement. ABP-450 contains Clostridium botulinum toxin, type A, with a molecular weight of 900 kDa, and is designed to address unmet medical needs in these therapeutic areas. AEON Biopharma's revenue model relies on future product sales and potential partnerships for ABP-450 development and commercialization. The company's primary products are ABP-450 for migraine prevention, cervical dystonia treatment, and gastroparesis management. These products target patients with chronic neurological and gastrointestinal conditions who require long-term therapeutic solutions. AEON Biopharma's development focus is on securing regulatory approvals for ABP-450 in these specific indications before pursuing commercialization. The firm does not currently have any marketed products or revenue streams, as it remains in the development phase. AEON Biopharma's target market segments include patients suffering from chronic migraine, cervical dystonia, and gastroparesis. These conditions affect individuals requiring ongoing medical intervention, with migraine patients seeking preventative care options. The company's development strategy centers on obtaining FDA approval for ABP-450 in these specific indications to enable future sales. AEON Biopharma's business model is based on the successful advancement of ABP-450 through clinical trials and regulatory pathways to achieve market entry. AEON Biopharma is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing AEON Biopharma's EBIT

AEON Biopharma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of AEON Biopharma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

AEON Biopharma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in AEON Biopharma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about AEON Biopharma stock

EBIT of AEON Biopharma is -12.80 M USD in 2025.

EBIT of AEON Biopharma changed from 72.99 M USD to -12.80 M USD, representing a -117.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT AEON Biopharma since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's AEON Biopharma historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — AEON Biopharma

All Key Metrics — AEON Biopharma